drugset / Trial / NCT01852539

Dexmedetomidine for Laryngeal Mask Airway Insertion

NCT01852539 ↗

Phase 4 Completed 22 enrolled Ajou University School of Medicine
NaSingle-groupDouble-blindTreatment

Summary

The investigators attempted to determine the optimal dose of dexmedetomidine required for the successful insertion of LMA during propofol induction without a neuromuscular blocking agent.

Timeline

Start
2013-07
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous
Background Propofol Small molecule 2 mg/kg —

Indications

No indication recorded.